RNA_Biotech retweeted
$MDNAF $MDNA.TO Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
ir.medicenna.com/news-releas…
RNA_Biotech retweeted
$MDNAF $MDNA.TO $XBI They have the Map. They have the Machine. They have the Workarounds. What they don’t have is the one layer that decides whether any of it actually works.
Tomorrow: first real look at MDNA113 — the conditionally activated bispecific designed to execute without recreating the failure mode.
open.substack.com/pub/davidb…
RNA_Biotech retweeted
As we prep to share our latest #MDNA113 data at #AACR26, the #ImmunoOncology space is officially heating up!
There is a MASSIVE push in pharma for PD-1 bispecifics. We're seeing >$43 BILLION in recent combined transaction value in this space alone. $MDNAF $MDNA.TO
ALT A text graphic with a dark cellular background. The text reads: Momentum in Immuno-Oncology. Strategic Signals in PD-1 Bispecifics. Greater than $43 Billion in recent combined transaction value." The Medicenna logo and #AACR26 hashtag are in the bottom corners.
RNA_Biotech retweeted
$MDNAF $MDNA.to to present MDNA-113 at #AACR26 04/21/2026
Notably, immunodynamic and safety data from non-human primate studies will highlight the differentiated profile of MDNA113
ir.medicenna.com/news-releas…
$MDNAF Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026 - Medicenna Therapeutics ir.medicenna.com/news-releas…
RNA_Biotech retweeted
$MDNAF $MDNA.TO The field has been waiting for a good IL-2 molecule.
We asked global KOLs from MD Anderson, Dana Farber, Roswell Park, and National Cancer Institute of Naples for their verdict on the latest #MDNA11 data presented at Melanoma Bridge and Immunotherapy Bridge at Naples.
Their take? Potentially "Best-in-Class." Watch the interviews:
RNA_Biotech retweeted
$MDNAF $MDNA.to $XBI PRISM-11 analysis of Medicenna ESMO press release: open.substack.com/pub/davidb…
RNA_Biotech retweeted
$MDNAF $MDNA.to abstract at #ESMO-IO - important to note it's not the final poster as it's only a place-holder data cutoff 09/04
More updated data with most likely mid November will be presented next week 12/10 at the conference!
The 2 slides are from AACR25 data cutoff 04/15/2025
RNA_Biotech retweeted
💡Tomorrow: Don’t miss @Medicenna1 live investor webinar
Join @Medicenna1 Therapeutics (TSX: $MDNA | OTCQX: $MDNAF) CEO Fahar Merchant as he reviews clinical progress and upcoming catalysts across the company’s #immunotherapy pipeline.
🔗 RSVP here >> bit.ly/4hRHTc5
#Biotech #CancerTherapy #LifeSciences #HealthcareInnovation #CancerResearch #DrugDiscovery
🧬 Clinical Stage Immune-Based Cancer Therapies
@Medicenna1 CEO Fahar Merchant provides an overview of $MDNA's multiple clinical and preclinical drug programs, highlighting numerous upcoming catalysts and value-creation events, and discussing how #Medicenna compares with recent billion-dollar transactions in its narrow field of drug developers.
🗓️ RSVP here to attend >> bit.ly/4hRHTc5
$MDNAF #Biotech #Immunotherapy #CancerResearch #LifeSciences #HealthcareInnovation
RNA_Biotech retweeted
And even better news, just to clarify, $MDNAF $MDNA.to isn’t funding the trial.
It’s being sponsored by the non-profit Melanoma Foundation (Fondazione Melanoma Onlus) at the National Cancer Institute ‘G. Pascale Foundation’.
Medicenna will provide the study drugs under a collaboration and supply agreement.
Now, $MDNAF $MDNA.to will have a new combo, with $BMY's nivolumab!!!
MDNA11 will be evaluated in combination with the checkpoint inhibitors nivolumab (anti-PD1) alone or with ipilimumab (anti-CTLA4), with Major Pathologic Response (MPR) as a primary endpoint, which is considered predictive of long-term survival outcomes.
RNA_Biotech retweeted
Now, $MDNAF $MDNA.to will have a new combo, with $BMY's nivolumab!!!
MDNA11 will be evaluated in combination with the checkpoint inhibitors nivolumab (anti-PD1) alone or with ipilimumab (anti-CTLA4), with Major Pathologic Response (MPR) as a primary endpoint, which is considered predictive of long-term survival outcomes.
This is really interesting step for $MDNAF "Neoadjuvant Combination Trial"
$MDNA.to Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma
ir.medicenna.com/news-releas…
RNA_Biotech retweeted
This is really interesting step for $MDNAF "Neoadjuvant Combination Trial"
$MDNA.to Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma
ir.medicenna.com/news-releas…
RNA_Biotech retweeted
$MDNA.TO $MDNAF Medicenna's updated MDNA11 clinical data from the Phase 1/2 ABILITY-1 Study will be presented at the @myESMO Immuno-Oncology Congress 2025 (Dec 10–12, London 🇬🇧).
Presented by Dr. André Mansinho, highlighting MDNA11 alone & with pembrolizumab.
#MDNA11 #ImmunoOncology #Biotech #ClinicalData #IMedicalResearch
ALT Updated MDNA11 Clinical Data to Be Presented at ESMO IO 2025
RNA_Biotech retweeted
The #IL2 space is gaining momentum!
$MDNAF's Best-in-Class IL-2 drug shows strong data as a mono and in combo with #Keytruda.
Next-gen MDNA113 outperforms IBI363, targeting IL-13Ra2 with a unique IL-13 binding epitope.
$TAK is paying $1.2B upfront for 2 candidates!
Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes $10.2 billion in milestones, puts the biologics at the center of Takeda’s push to establish growth drivers for the post-Entyvio era. fiercebiotech.com/biotech/ta…
RNA_Biotech retweeted
$MDNAF $MDNA.TO Medicenna will present and participate 1x1 meetings at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York City.
Live Webcast 🔗: journey.ct.events/view/4f164…
Schedule a 1-on-1 meeting 🔗: hcwevents.com/annualconferen…
Investor Relations: ✉️[email protected] or 📞(416)964-5442
#Biotech #Immunotherapy #HCWainwright2025 #MDNA
ALT Medicenna to present at H.C. Wainwright 27th Annual Global Investment Conference
RNA_Biotech retweeted
$MDNAF $MDNA.TO Big news! Medicenna Therapeutics just strengthened its IP portfolio with 5 new patents granted for our IL-2 and IL-4 Superkine platforms! These secure broad protection & enhance the commercial potential of our programs, including MDNA11 & bizaxofusp. Our global IP now totals 86 patents!
Read more: ir.medicenna.com/news-releas…
#Medicenna #Immunotherapy #Patents #Superkines #Biotech
RNA_Biotech retweeted
$MDNAF $MDNA.TO BIG NEWS! Medicenna reports in exciting Fiscal Year 2025 with compelling progress!
✨MDNA11: Best-in-class potential continues, with a pancreatic cancer patient in remission for 18+ months! More updates H2 2025!
🚀MDNA113: Our novel PD-1 x IL-2 bispecific program is advancing to non-human primate studies H2 2025!
💰Strong Financials: Robust cash position provides runway into at least mid-2026!
Read the full story: ir.medicenna.com/news-releas…
#Biotech #CancerResearch #Oncology #ClinicalTrials #PatientCare #Medicenna #MDNA11 #MDNA113
